Burlet B, Ramla S, Fournier C, Abrey-Recalde MJ, Sauter C, Chrétien ML, Rossi C, Duffourd Y, Ragot S, Buriller C, Tournier B, Chapusot C, Nadal N, Racine J, Guy J, Bailly F, Martin L, Casasnovas O, Bastie JN, Caillot D, Albuisson J, Broccardo C, Thieblemont C, Delva L, Maynadié M, Aucagne R, Callanan MB

Cold Spring Harb Mol Case Stud. 2021 Feb;7(1):

High-fat diet intensifies MLL-AF9-induced acute myeloid leukemia through activation of the FLT3 signaling in mouse primitive hematopoietic cells.

Hermetet F, Mshaik R, Simonet J, Callier P, Delva L, Quéré R

. 2020 Sep 30;10(1):16187

T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7.

Buffière A, Uzan B, Aucagne R, Hermetet F, Mas M, Nassurdine S, Aznague A, Carmignac V, Tournier B, Bouchot O, Ballerini P, Barata JT, Bastie JN, Delva L, Pflumio F, Quéré R

Oncogene. 2019 Aug 15;:

Serpin B1 defect and increased apoptosis of neutrophils in Cohen syndrome neutropenia.

Duplomb L, Rivière J, Jego G, Da Costa R, Hammann A, Racine J, Schmitt A, Droin N, Capron C, Gougerot-Pocidalo MA, Dubrez L, Aral B, Lafon A, Edery P, Ghoumid J, Blair E, El Chehadeh-Djebbar S, Carmignac V, Thevenon J, Guy J, Girodon F, Bastie JN, Delva L, Faivre L, Thauvin-Robinet C, Solary E

J. Mol. Med.. 2019 Mar 7;:

High-fat diet disturbs lipid raft/TGF-β signaling-mediated maintenance of hematopoietic stem cells in mouse bone marrow.

Hermetet F, Buffière A, Aznague A, Pais de Barros JP, Bastie JN, Delva L, Quéré R

Nat Commun. 2019 Jan 31;10(1):523

Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.

Buffière A, Accogli T, Saint-Paul L, Lucchi G, Uzan B, Ballerini P, Bastie JN, Delva L, Pflumio F, Quéré R

Leukemia. 2018 Feb 28;:

[CD45 phosphatase, a relevant target for the treatment of acute myeloid leukemia].

Saint-Paul L, Nguyen CH, Bastie JN, Delva L, Quéré R

Med Sci (Paris). 2016 Dec;32(12):1051-1053

CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts.

Saint-Paul L, Nguyen CH, Buffière A, Pais de Barros JP, Hammann A, Landras-Guetta C, Filomenko R, Chrétien ML, Johnson P, Bastie JN, Delva L, Quéré R

Oncotarget. 2016 10;7(40):64785-64797

Trim33/Tif1γ is involved in late stages of granulomonopoiesis in mice.

Chrétien ML, Legouge C, Martin RZ, Hammann A, Trad M, Aucagne R, Largeot A, Bastie JN, Delva L, Quéré R

Exp. Hematol.. 2016 Aug;44(8):727-739.e6

[A novel mouse model to study physiological aging of haematopoietic cells].

Quere R, Bastie JN, Delva L

Med Sci (Paris). 2014 Dec;30(12):1076-8

Tif1gamma regulates the TGF-beta1 receptor and promotes physiological aging of hematopoietic stem cells.

Quere R, Saint-Paul L, Carmignac V, Martin RZ, Chretien ML, Largeot A, Hammann A, Pais de Barros JP, Bastie JN, Delva L

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10592-7

Cohen syndrome is associated with major glycosylation defects.

Duplomb L, Duvet S, Picot D, Jego G, El Chehadeh-Djebbar S, Marle N, Gigot N, Aral B, Carmignac V, Thevenon J, Lopez E, Riviere JB, Klein A, Philippe C, Droin N, Blair E, Girodon F, Donadieu J, Bellanne-Chantelot C, Delva L, Michalski JC, Solary E, Faivre L, Foulquier F, Thauvin-Robinet C

Hum Mol Genet. 2014 May 1;23(9):2391-9

Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.

Largeot A, Paggetti J, Broseus J, Aucagne R, Lagrange B, Martin RZ, Berthelet J, Quere R, Lucchi G, Ducoroy P, Bastie JN, Delva L

Biochim Biophys Acta. 2013 Dec;1833(12):3054-63

A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages.

Lagrange B, Martin RZ, Droin N, Aucagne R, Paggetti J, Largeot A, Itzykson R, Solary E, Delva L, Bastie JN

Biochim Biophys Acta. 2013 Aug;1833(8):1936-46

[MiR-142-3p in leukaemogenesis: tumour suppressor or oncomiR?].

Lagrange B, Martin RZ, Droin N, Solary E, Bastie JN, Delva L

Med Sci (Paris). 2013 Jun-Jul;29(6-7):574-6

Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.

Bastie JN, Aucagne R, Droin N, Solary E, Delva L

Cell Mol Life Sci. 2012 Sep;69(17):2853-61

[TIF1gamma: a tumor suppressor gene in chronic myelomonocytic leukemia].

Aucagne R, Droin N, Solary E, Bastie JN, Delva L

Med Sci (Paris). 2011 Aug-Sep;27(8-9):696-8

Cellular Inhibitor of Apoptosis Protein-1 (cIAP1) Can Regulate E2F1 Transcription Factor-mediated Control of Cyclin Transcription.

Cartier J, Berthelet J, Marivin A, Gemble S, Edmond V, Plenchette S, Lagrange B, Hammann A, Dupoux A, Delva L, Eymin B, Solary E, Dubrez L

J Biol Chem. 2011 Jul 29;286(30):26406-17

Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.

Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, Losson R, Solary E, Bastie JN, Delva L

J Clin Invest. 2011 Jun 1;121(6):2361-70

Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.

Paggetti J, Largeot A, Aucagne R, Jacquel A, Lagrange B, Yang XJ, Solary E, Bastie JN, Delva L

Oncogene. 2010 Sep 9;29(36):5019-31

A role for the transcription intermediary factor 2 in zebrafish myelopoiesis.

Zhuravleva J, Solary E, Chluba J, Bastie JN, Delva L

Exp Hematol. 2008 May;36(5):559-67

1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells.

Bastie JN, Balitrand N, Guidez F, Guillemot I, Larghero J, Calabresse C, Chomienne C, Delva L

Mol Endocrinol. 2004 11;18(11):2685-99

Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II.

Despouy G, Bastie JN, Deshaies S, Balitrand N, Mazharian A, Rochette-Egly C, Chomienne C, Delva L

J. Biol. Chem.. 2003 Feb;278(8):6355-62

The novel co-activator CRABPII binds to RARalpha and RXRalpha via two nuclear receptor interacting domains and does not require the AF-2 'core'.

Bastie JN, Despouy G, Balitrand N, Rochette-Egly C, Chomienne C, Delva L

FEBS Lett.. 2001 Oct;507(1):67-73

Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex.

Delva L, Bastie JN, Rochette-Egly C, Kraïba R, Balitrand N, Despouy G, Chambon P, Chomienne C

Mol. Cell. Biol.. 1999 Oct;19(10):7158-67

[Nuclear receptors and ontogenesis of the hematopoietic tissue].

Chomienne C, Guidez F, Micléa JM, Bastie JN, Delva L, Rousselot P, Ballerini P

C R Seances Soc Biol Fil. 1995 ;189(4):493-501

Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells.

Delva L, Cornic M, Balitrand N, Guidez F, Micléa JM, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L

Blood. 1993 Oct;82(7):2175-81

Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients.

Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C

Cancer Res. 1992 06 15;52(12):3329-34

[Mechanism of action of retinoids in a new therapeutic approach to acute promyelocytic leukemia].

Cornic M, Guidez F, Delva L, Agadir A, Degos L, Chomienne C

Bull Cancer. 1992 ;79(7):697-704

Dr DELVA Laurent

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Site web

Recherche

Projets

Publications